Abstract
The majority of Men C conjugate vaccines given in the UK use CRM(197), a mutant diphtheria toxoid, as their protein carrier. We studied the effects of prior immunisation with Men C-CRM(197) conjugate vaccine on immunity to diphtheria in 193 children before and after a booster dose of Men C at 4 years. Baseline diphtheria antibodies were higher in children given four previous doses of Men C (P<0.0001) and tended to be higher following boosting in those who had received three or four doses. This enhanced immunity was not associated with increased reactogenicity.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Child, Preschool
-
Diphtheria / immunology*
-
Diphtheria / prevention & control
-
Diphtheria Toxoid / adverse effects
-
Diphtheria Toxoid / immunology
-
Diphtheria Toxoid / therapeutic use*
-
Follow-Up Studies
-
Humans
-
Immunization Schedule
-
Infant
-
Meningococcal Infections / immunology*
-
Meningococcal Infections / prevention & control
-
Meningococcal Vaccines / adverse effects
-
Meningococcal Vaccines / immunology
-
Meningococcal Vaccines / therapeutic use*
-
Reproducibility of Results
-
Time Factors
-
Vaccines, Conjugate / adverse effects
-
Vaccines, Conjugate / immunology
-
Vaccines, Conjugate / therapeutic use*
Substances
-
Diphtheria Toxoid
-
Meningococcal Vaccines
-
Vaccines, Conjugate